Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 20/20 | 1.00 |
| ▸ | HTR1B | P28222 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578909 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7477276 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL4577556 | 0.91 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL4355208 | 0.90 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL4578276 | 0.90 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL7474266 | 0.90 | HTR1D (1.00) | HTR1DHTR1B | |
| SCHEMBL4578434 | 0.89 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL7481503 | 0.89 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL4579728 | 0.89 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL8648282 | 0.85 | HTR1D (0.74) | HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796675-A4 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO INC (US) | 2009-03-04 | — | — | EP | claimed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | claimed |
| EP-1796675-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006039252-A2 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | claimed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | claimed |
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096859-A1 | Compositions and Methods for Treating Ophthalmic Diseases | CXCL12, CXCR4, CX3CR1 | HTR1D 3404/4885HTR1B 3286/4885HTR1A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.